Page 51 - IJB-10-5

International Journal of Bioprinting Bioprinted tumor immune microenvironment

18 Gross G, Waks T, Eshhar Z. Expression of immunoglobulin- 32. Ito H, Seishima M. Regulation of the induction and function
T-cell receptor chimeric molecules as functional receptors of cytotoxic T lymphocytes by natural killer T cell. J Biomed
with antibody-type specificity. Proc Natl Acad Sci U S A. Biotechnol. 2010;2010:641757.
1989;86(24):10024-10028. doi: 10.1155/2010/641757
doi: 10.1073/pnas.86.24.10024
33. Zanna MY, Yasmin A, Omar AR, et al. Review of
19. Schlom J. Therapeutic cancer vaccines: current status and dendritic cells, their role in clinical immunology, and
moving forward. J Natl Cancer Inst. 2012;104(8):599-613. distribution in various animal species. Int J Mol Sci. 2021;
doi: 10.1093/jnci/djs033 22(15):8044.
doi: 10.3390/ijms22158044
20 Finn OJ. Cancer vaccines: between the idea and the reality.
Nat Rev Immunol. 2003;3(8):630-641. 34. Xiao Z, Wang R, Wang X, et al. Impaired function of
doi: 10.1038/nri1150 dendritic cells within the tumor microenvironment. Front
Immunol. 2023;14:1213629.
21 Mou P, Ge QH, Sheng R, et al. Research progress on the doi: 10.3389/fimmu.2023.1213629
immune microenvironment and immunotherapy in gastric
cancer. Front Immunol. 2023;14:1291117. 35. Lendeckel U, Venz S, Wolke C. Macrophages: shapes and
doi: 10.3389/fimmu.2023.1291117 functions. ChemTexts. 2022;8(2):12.
doi: 10.1007/s40828-022-00163-4
22 Chen C, Liu X, Chang CY, et al. The interplay between
T cells and cancer: the basis of immunotherapy. Genes. 36. Vivier E, Tomasello E, Baratin M, et al. Functions of natural
2023;14(5):1008. killer cells. Nat Immunol. 2008;9(5):503-510.
doi: 10.3390/genes14051008 doi: 10.1038/ni1582
23. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and 37. Mu P, Zhou S, Lv T, et al. Newly developed 3D in vitro
immunity. Cell Death Differ. 2010;17(4):616-623. models to study tumor–immune interaction. J Exp Clin
doi: 10.1038/cdd.2009.206 Cancer Res. 2023;42(1):81.
doi: 10.1186/s13046-023-02653-w
24. Navasardyan I, Bonavida B. Regulation of T cells in cancer
by nitric oxide. Cells. 2021;10(10):2655. 38. Zschaler J, Schlorke D, Arnhold J. Differences in innate
doi: 10.3390/cells10102655 immune response between man and mouse. Crit Rev
Immunol. 2014;34(5):433-454.
25. McDonnell AM, Robinson BW, Currie AJ. Tumor antigen
cross‐presentation and the dendritic cell: where it all begins? doi: 10.1615/CritRevImmunol.2014011600
J Immunol Res. 2010;2010(1):539519. 39. Bjornson-Hooper ZB, Fragiadakis GK, Spitzer MH, et al. A
doi: 10.1155/2010/539519 comprehensive atlas of immunological differences between
humans, mice, and non-human primates. Front Immunol.
26. Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: 2022;11(13):867015.
an accomplice in solid tumor progression. J Biomed Sci. doi: 10.3389/fimmu.2022.867015
2019;26(1):78.
doi: 10.1186/s12929-019-0568-z 40. Zhao Z, Zhang S, Jiang N, et al. Patient-derived
immunocompetent tumor organoids: a platform
27. Yu Y. The function of NK cells in tumor metastasis and NK
cell-based immunotherapy. Cancers. 2023;15(8):2323. for chemotherapy evaluation in the context of
doi: 10.3390/cancers15082323 T-cell recognition. Angew Chem Int Ed. 2024;63(9):
e202317613.
28. Gabrilovich D. Mechanisms and functional significance of doi: 10.1002/anie.202317613
tumour-induced dendritic-cell defects. Nat Rev Immunol. 41. Goldenson BH, Hor P, Kaufman DS. iPSC-derived natural
2004;4(12):941-952. killer cell therapies-expansion and targeting. Front Immunol.
doi: 10.1038/nri1498
2022;3(13):841107.
29. Melief CJ. Cancer immunotherapy by dendritic cells. doi: 10.3389/fimmu.2022.841107
Immunity. 2008;29(3):372-383. 42. Minagawa A, Yoshikawa T, Yasukawa M, et al. Enhancing
doi: 10.1016/j.immuni.2008.08.004
T cell receptor stability in rejuvenated iPSC-derived T cells
30. Shurin GV, Ma Y, Shurin MR. Immunosuppressive improves their use in cancer immunotherapy. Cell Stem Cell.
mechanisms of regulatory dendritic cells in cancer. Cancer 2018;23(6):850-858.e4.
Microenviron. 2013;6(2):159-167. doi: 10.1016/j.stem.2018.10.005
doi: 10.1007/s12307-013-0133-3
43. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human
31. Cess CG, Finley SD. Multi-scale modeling of macrophage—T iPSC-derived natural killer cells engineered with chimeric
cell interactions within the tumor microenvironment. PLoS antigen receptors enhance anti-tumor activity. Cell Stem
Comp Biol. 2020;16(12):e1008519. Cell. 2018;23(2):181-192.e5.
doi: 10.1371/journal.pcbi.1008519 doi: 10.1016/j.stem.2018.06.002

Volume 10 Issue 5 (2024) 43 doi: 10.36922/ijb.3988